Incyte (INCY) Free Cash Flow (2010 - 2026)
Incyte (INCY) reported Free Cash Flow of $359.2 million for Q1 2026, up 36.61% on a YoY basis from $262.9 million in Q1 2025, and down 26.49% quarter-over-quarter from $488.6 million in Q4 2025.
Incyte (INCY) Free Cash Flow (2010 - 2026) Analysis & Trends
Incyte has reported Free Cash Flow for 17 years, with the latest figure at $359.2 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 36.61% year-over-year to $359.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 284.64% YoY), and the FY2025 full-year result was $1.4 billion, up 307.11% from the prior year.
- Free Cash Flow for Q1 2026 stood at $359.2 million, down from $488.6 million in the prior quarter.
- The five-year high for Free Cash Flow was $559.3 million in Q3 2025, with the low at -$576.0 million in Q2 2024.
- Historically, Free Cash Flow has averaged $204.5 million across 5 years, with a median of $262.9 million in 2025.
- The largest YoY upside for Free Cash Flow was 285.88% in 2024 against a maximum downside of 292.51% in 2024.
- Incyte's Free Cash Flow stood at $336.7 million in 2022, then sank by 65.77% to $115.3 million in 2023, then surged by 231.58% to $382.2 million in 2024, then advanced by 27.85% to $488.6 million in 2025, then fell by 26.49% to $359.2 million in 2026.
- The last three Free Cash Flow figures came in at $359.2 million (Q1 2026), $488.6 million (Q4 2025), and $559.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 359.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 359.15 Mn |
| Mar 31, 2026 | 359.15 Mn |
| Dec 31, 2025 | 488.59 Mn |
| Dec 31, 2025 | 488.59 Mn |
| Sep 30, 2025 | 559.28 Mn |
| Sep 30, 2025 | 559.28 Mn |
| Jun 30, 2025 | 43.86 Mn |
| Jun 30, 2025 | 43.86 Mn |
| Mar 31, 2025 | 262.90 Mn |
| Mar 31, 2025 | 262.90 Mn |
| Dec 31, 2024 | 382.16 Mn |
| Dec 31, 2024 | 382.16 Mn |
| Sep 30, 2024 | 308.13 Mn |
| Sep 30, 2024 | 308.13 Mn |
| Jun 30, 2024 | -575.98 Mn |
| Jun 30, 2024 | -575.98 Mn |
| Mar 31, 2024 | 218.43 Mn |
| Mar 31, 2024 | 218.43 Mn |
| Dec 31, 2023 | 115.25 Mn |
| Dec 31, 2023 | 115.25 Mn |